NEW: Two papers by the #WBMT review endemic or regionally limited #infections in haematopoietic stem-cell transplantation recipients #bmtsm Mahmoud Aljurf 1⃣ Viral and bacterial infections 🦠thelancet.com/journals/lanha… 2⃣ Fungal and parasitic infections🦟thelancet.com/journals/lanha…

Inequalities in the career pathway for paediatric HSCT and cellular therapy physicians 👉out in The Lancet Haematology 👉doi.org/10.1016/S2352-… congrats to all The EBMT Trainee Committee members!!

Out today in The Lancet Haematology 🎉 Great work by Carmelo Gurnari Claire Horgan et al. Thank you guys for making me a part of this collaborative effort 🙏🏻 #MedTwitter

Our incredible PGY5 Ibrahim Muhsen on the podium and giving an excellent talk on safety and efficacy of brexu-cel for ALL with CNS involvement at #Tandem24

Had a great time attending #Tandem24 for the first time in-person! It was great meeting friends, colleagues, leaders in the field and mentors! Mahmoud Aljurf LaQuisa Hill sganguly

It's been a fantastic journey from a bench discovery to a Phase 1 trial led Center for Cell and Gene Therapy by LaQuisa Hill and Rayne Rouce. Excited for new options for in T-cell malignancies and look forward to the upcoming Phase 2. houstonchronicle.com/health/article…

Please join us in warmly welcoming our new Chief Residents, Haneen Salah & Shandice Waugh, along with our Chief Fellow, John Rogers, for the 2024-25 academic year! 🎉 Their vision and commitment to #LeadingMedicine will allow us to continue setting the standard for excellence.

Read our article: Efficacy of Letermovir for CMV Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant. astctjournal.org/article/S2666-…

Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies Transplantation and Cellular Therapy Journal astctjournal.org/article/S2666-…

Out in Journal of Clinical Oncology! Glad to be part of this effort. 189 r/r ALL pts post brexu-cel: -mFU: 11.4 mons -mLOT=4 -12-mons OS: 63%, mOS: not reached -12-mons PFS: 48%, mPFS: 9.5 mons -G3-4 CRS: 11% -G3-4 ICANS: 31% Congratulations to Greg Roloff, Lori Muffly & the ROCCA team.

👉Cellular therapies for acute leukemia: A Deep Dive from #ASH24 🚩21/21 🧵 🙏Feel free to add any other relevant abstract #AML #TALL #BALL #ASH24rm ASH

#ASH24 ASH #mmsm Approved BsAbs in Hematologic Malignancies

I just met an amazing rockstar fellow, Ibrahim Muhsen ASH #ASH24! I can already tell he’s going to shine bright in the Lymphoma world!

What a great talk Ibrahim- go BCM fellow

Brexu-Cel Displays Comparable Efficacy Across Age Groups in Relapsed/Refractory B-ALL Ibrahim Muhsen ASH #ASH24 #oncology #Med #MedTwitter #leusm onclive.com/view/brexu-cel…

Great talk by Ibrahim Muhsen from our very own BCM Hematology-Oncology Fellowship on CAR-T with brexu-cel for B-ALL in 60 and above. Impressive multi-institutional work!

Attending #ASH24 was a blast, from ASH-a-Palooza and meeting new trainees to reconnecting with med school seniors Syeda Mina Ibrahim Muhsen and mentors Mansour. Can't wait for the next one in Orlando next year!